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This study was performed to investigate the effect of curcumin on cardiac myosin-
-induced autoimmune myocarditis in rats and the change in thioredoxin (TRX) 
immunoreactivity in cardiomyocytes following curcumin treatment. Twenty-four 
six-week-old male Wistar rats were randomly allocated into 4 groups of 6 rats each. 
Group I received neither curcumin nor myosin. Group II received an oral solution 
of 1 g/kg/day of curcumin daily, from day 1 to day 21. To induce myocarditis, 
animals of both group III and group IV were injected by 1 mg of porcine cardiac 
myosin on days 1 and 8. In addition, animals of group IV received an oral solution 
of 1 g/kg/day of curcumin daily, from day 1 to day 21. Serum levels of creatine 
phosphokinase, troponin-T, tumour necrosis factor-alpha and interleukin-6 were 
estimated. Hearts were processed for histopathological and immunohistochemical 
studies. Serum biomarkers levels were significantly increased in myocarditis group 
as compared to other groups. The intake of curcumin significantly reduced the 
deviation in these markers. Sections of the wall of the heart from myocarditis 
group were characterised by inflammatory cell infiltration. Most of cardiomyocy-
tes showed pyknotic nuclei and increased sarcoplasmic eosinophilia with strong 
immunoreactivity for TRX. Sections from myocarditis-curcumin group showed 
normal architecture with moderate immunoreactivity for TRX. The present study 
demonstrated that curcumin ameliorates acute myocarditis in rats and encouraged 
the estimation of serum level of TRX as a relevant indicator for the evaluation of 
the progress of acute myocarditis. (Folia Morphol 2015; 74, 3: 318–324)
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INTRODUCTION
Heart disease is one of the major health problems 
of advanced as well as developing countries in the 
world. In human, acute myocarditis is a potentially 
lethal disease, and frequently precedes the deve-
lopment of dilated cardiomyopathy [2].
Myocarditis is defined as myocardial inflammation 
accompanied with oedema, cellular infiltration, apo-
ptosis, and necrosis of cardiomyocytes [13]. In acute 
myocarditis, an imbalance of the reactive oxygen spe-
cies (ROS) and/or an inadequate cellular antioxidant 
defence mechanism may play a key role in myocardial 
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injury [20]. Increased ROS are able to induce severe 
cardiovascular dysfunction by their direct attack on 
intercellular biomolecules such as contractile mole-
cules or ion channels. Also, the imbalance of intra-
cellular oxido-reductive state (redox) may lead to the 
activation of stress sensitive signalling pathways, 
increasing apoptosis and potentially contributing to 
the development of heart failure [18].
Cells have developed elaborate defence systems 
against oxidative stresses. Among those, a pivotal 
role of the thiol-mediated redox systems has been 
recognised. Thioredoxin (TRX) is a redox regulatory 
protein that protects the cells from various stresses by 
reducing activity of oxidised thiol groups on proteins. 
It was reported that TRX is up-regulated by acute 
inflammatory stimuli and may play an important 
protective role in the pathogenesis and development 
of myocarditis [14]. There are two major TRX: thio-
redoxin 1 (TRX1), a cytosolic and nuclear form, and 
thioredoxin 2 (TRX2), a mitochondrial form [16]. TRX1 
binds with a variety of cellular proteins and inhibits 
apoptosis [1].
Cardiac myosin-induced myocarditis is a model 
of experimental autoimmune myocarditis (EAM) in 
rats to investigate autoimmunological mechanisms in 
inflammatory heart diseases. During the development 
of the disease, myosin first elicits a focal inflammation 
mediated by neutrophil and macrophage infiltration, 
which then triggers the activation of mononuclear 
effector cells and initiates the EAM [3]. This model of 
EAM is histologically similar to human myocarditis in 
acute phase, with the recruitment of macrophages, 
lymphocytes and neutrophils accompanying myocar-
dial fibrosis [8, 20].
Curcumin, a yellow pigment from Curcuma longa, 
is a major component of turmeric and is commonly 
used as a spice and food-colouring agent by more 
than 1 billion people [6, 11]. Curcumin has a surpri-
singly wide range of beneficial properties, including 
anti-inflammatory, antioxidant, chemopreventive and 
chemotherapeutic activity [4]. It exhibits a great pro-
mise as a therapeutic agent, and is currently used 
in human clinical trials for a variety of conditions, 
including heart diseases [18]. 
This study was performed to investigate whether 
oral curcumin treatment has any protective effect on 
cardiac myosin-induced autoimmune myocarditis in 
rats and to demonstrate the possible changes in TRX 
expression in cardiomyocytes following curcumin 
treatment.
MATERIALS AND METHODS
The study was conducted in the Department of 
Anatomy, College of Medicine, King Saud University, 
Riyadh, Kingdom of Saudi Arabia. The study was 
approved by the Research Ethical Committee of the 
College of Medicine, King Saud University (approval 
No. 11/2882/IRB).
Animals
Twenty-four six-week-old male Wistar rats, wei-
ghing about 200–250 g, were housed under standard 
environmental conditions with free access to standard 
pelleted rat chow and tap water. The study followed 
the International Guidelines for the Care and Use of 
Laboratory Animals for experimental procedure. 
Study design
Animals were randomly allocated into 4 groups 
of 6 rats each.
—  Group I (untreated control group) — rats recei-
ved neither curcumin nor myosin;
—  Group II (curcumin-exposed group) — rats re-
ceived curcumin in water, orally, at the dose of 
1 g/kg/day [6], from day 1 to day 21;
—  Group III (myocarditis group) — rats were im-
munised with 1 mg of porcine cardiac myosin on 
day 1 and day 8 [3, 10, 12, 14];
—  Group IV (myocarditis-curcumin group) — rats 
were immunised with 1 mg of porcine cardiac 
myosin on day 1 and day 8, and received curcumin 
in water, orally, at the dose of 1 g/kg/day, from 
day 1 to day 21. 
All animals were sacrificed on day 22 by cervical 
decapitation under ether anaesthesia. Truncal blood 
was collected and serum was separated from each 
animal for biochemical assay. The hearts were excised 
and processed for histological and immunohistoche-
mical studies.
Induction of EAM by immunisation. The rats 
were injected subcutaneously, in the back, on days 1 
and 8, with 1 mg (0.1 mL) of purified porcine cardiac 
myosin (10 mg/mL) (M 0531-10MG, Myosin, calcium 
activated, from porcine heart; buffered aqueous gly-
cerol solution 1.05 mL; 9.5 mg protein/mL, Sigma-
-Aldrich Chemical Company, St. Louis, MO, USA) 
emulsified in an equal volume of complete Freund’s 
adjuvant supplemented with mycobacterium tuber-
culosis H37Ra (DifcoLab., Detroit, MI, USA). Both 
control and control-curcumin groups were injected 
with complete Freund’s adjuvant alone.
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The digital slide images were then viewed and 
analysed using the viewing and image analysis tools 
of Aperio’s ImageScope software. Five areas, each 
with the fixed size of 137,000 μm2, were randomly 
selected per section. To quantify the immunoposi-
tivity, the colour deconvolution (colour separation) 
algorithm (Aperio Technologies, Inc.) was set up 
(by colour calibration) so as to detect and quantify 
only the brown colour of DAB positive staining. 
The algorithm was then run on the selected area 
to measure the percentage of immumopositivity 
relative to the area being measured. The analysis 
output results were finally exported to Excel sheets 
and subjected to statistical analysis.
Serum biochemical analysis
Determination of cardiac injury markers levels. 
Serum troponin-T concentration was determined us-
ing a Siemens Dimension Xpand® Plus instrument (IL, 
USA). Serum creatine phosphokinase MB isoenzyme 
(CPK-MB) level was measured with an auto-analyser 
(ILab-300 bioMérieux Diagnostics, Milan, Italy).
Determination of tumour necrosis factor-alpha 
(TNF-a) level. The concentration of the inflammatory 
cytokine TNF-a in serum was determined using com-
mercially available enzyme-linked immunosorbent 
assay ELISA kits following the instructions supplied 
by the manufacturer (DuoSet kits, R&D Systems; Min-
neapolis, MN, USA). The results were shown as pg of 
cytokine per mL.
Determination of interleukin-6 (IL-6) level. The 
IL-6 levels were measured by ultra-sensitive ELISA 
(Quantikine HS Human IL-6 Immunoassay; R&D Sy-
stems, Minneapolis, MN) with an analytical concentration 
value of 6.3% and a detection level of 0.04 pg/mL [5].
Statistical analysis
Data collected were subjected to statistical analysis 
using IBM SPSS Statistics version 22 software. The 
homogeneity of the obtained numerical data was first 
checked with Levene test and the homogeneity of va-
riance assumption has been met. Analysis of variance 
(ANOVA) was used for an overall comparison between 
the study groups followed by Bonferroni as a post-hoc 
test for pairwise comparisons. Differences were con-
sidered significant when p was equal to or less than 
0.05. A 95% confidence level was used to calculate 
a confidence interval, which is a range of values around 
the mean where the “true” (population) mean can be 
expected to be located, with 95% certainty.
Histological study
The excised hearts were fixed in 10% buffered 
formalin at 4oC for 24 h and processed to prepare 
transverse mid-ventricular 5-μm-thick paraffin sections. 
These sections were stained with haematoxylin and 
eosin (H&E) (Haematoxylin, Sigma, Life Science, product 
code 1001011134, USA — Eosin Y, Sigma-Aldrich, Batch 
#01005 LE, USA). Myocarditis was determined by iden-
tifying both infiltrating mononuclear cells and necrosis 
of cardiomyocytes [8]. The percentage of myocarditis 
was assessed semiquantitatively, according to the scale: 
0 — normal; 1 — mild (< 5% of heart cross-section 
involved); 2 — moderate (5–10% of cross-section invol-
ved); 3 — marked (10–25% of cross-section involved); 
and 4 — severe (> 25% of cross-section involved) [7, 8].
Immunohistochemical study
Immunostaining of mid-ventricular paraffin sections 
of the heart for detection of TRX [14] was performed 
using streptavidin-biotinylated horseradish peroxidase 
(S-ABC) method (Novalink Max Polymer detection sys-
tem, Novocastra, product NO. RE7280-K). The procedure 
involved the following steps: endogenous peroxidase 
activity was inhibited by 3% H2O2 in distilled water for 
5 min, and then the sections were washed in Tris buff-
ered saline (TRS) (Sigma, T 5030-100 TAB, pH 7.6) for 
10 min. Non-specific binding of antibodies was blocked 
by incubation with protein block for 5 min (Novocastra). 
Sections were incubated with rabbit polyclonal anti-rat 
TRX, Abcam, Cat# ab26320 (100 μg, 0.4 mg/mL), di-
luted 1:200 for 1 h at room temperature. Sections were 
washed in Tris buffer for 3 times, each for 3 min, and 
then incubated with biotinylated anti-rabbit IgG (Novo-
castra) for 30 min. This was followed by washing in Tris 
buffer for 3 times, each for 3 min, and then incubated 
with Novolink polymer (Novocastra) for 30 min. Then 
sections were washed in Tris buffer for 3 times, each for 
3 min. Peroxidase was detected with working solution of 
diaminobenzedine (DAB) substrate (Novocastra) for 10 
min. Finally, sections were washed in distilled water for 
10 min, nuclei were stained with Mayer’s haematoxylin 
and sections were mounted in DPX (Dystyrene, Plasti-
cizer, Xylene). For negative control sections, the same 
procedure was followed with omission of incubation in 
rabbit polyclonal anti-rat TRX.
Image analysis
High-resolution whole-slide digital scans of all 
TRX-immunostained sections were created with 
a ScanScope scanner (Aperio Technologies, Inc.). 
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RESULTS
The body weight of animals of myocarditis group 
was decreased, while the body weight of the ani-
mals of the other groups was markedly increased. 
The daily food and water consumption was reduced 
in animals of myocarditis group compared to the 
animals of the other groups. There was a marked 
decrease in the movements and activities of animals 
of myocarditis group compared to the animals of 
the other groups.
Histological study
H&E-stained sections of the wall of the mid-ven-
tricular level of the heart from all rats of Group I 
and Group II showed normal architecture of cardio-
myocytes and endomysium (Fig. 1A, B). There were 
no pyknotic nuclei in the cardiomyocytes of both 
groups (Table 1). H&E-stained sections of all rats of 
Group III showed evidence of severe myocarditis, in 
the form of inflammatory cell infiltration, swelling 
of cardiomyocytes, interstitial oedema, increased 
sarcoplasmic eosinophilia and increased number 
of cardiomyocytes with pyknotic nuclei (Fig. 1C). 
The mean percentage of pyknotic nuclei in cardio-
myocytes of autoimmune myocarditis animals was 
58.468 ± 4.976% of the total number of cardio-
myocytes (Table 1). H&E-stained sections of rats of 
Group IV showed normal architecture in almost all 
cardiomyocytes and endomysium (Fig. 1D). Mild 
focal myocarditis (< 5% of the total areas of the 
examined sections) was evident in the sections of 
this group. The mean percentage of pyknotic nuclei 
in cardiomyocytes showed a significant decrease to 
31.244 ± 5.670% compared to Group III (Table 1). 
Figure 1. Heart sections stained with haematoxylin and eosin. A. Heart of rat from untreated control group; B. Heart of rat from curcumin-
-exposed group, showing normal architecture; C. Heart of rat from myocarditis group, showing necrotic cardiomyocytes (arrows); D. Heart  
of rat from myocarditis-curcumin group, showing normal architecture. Scale bars = 50 µm.
Table 1. Percentage of pyknotic nuclei in cardiomyocytes
Group I: 
Control
Group II: 
Control–curcumin
Group III: 
Myocarditis
Group IV: 
Myocarditis–curcumin
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI
Mean  
± SD
0.000  
± 0.000
0.000–0.000 0.000  
± 0.000
0.000–0.000 58.468  
± 4.976
53.246– 
–63.690
31.244  
± 5.670
27.188– 
–35.300
P1 1.000 0.0002* 0.0002*
P2 1.000 0.0002* 0.0002*
P3 0.0002* 0.0002* 0.0002*
*Significant difference (p ≤ 0.05); CI — confidence interval; SD — standard deviation; P1 vs. Group I; P2 vs. Group II; P3 vs. Group III
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Immunohistochemical study
Immunohistochemistry was performed to determine 
the histological localisation of TRX in the heart. Sections 
of the heart from Group I and Group II showed moderate 
immunoreactivity for TRX in the sarcoplasm, while nuclei 
of cardiomyocytes were not immunostained. The extent 
of immunopositivity, expressed as mean area per cent 
of strong positivity, in Group I and Group II measured 
16.003 ± 4.139% and 14.660 ± 9.977%, respectively 
(Table 2). All sections of the heart from Group III showed 
strong immunoreactivity for TRX in the sarcoplasm and 
almost all nuclei of cardiomyocytes (Fig. 2C). This group 
showed significant increase in the mean area per cent 
of strong positivity to 39.777 ± 7.297%, compared to 
Group I and Group II (Table 2). Sections of the heart from 
Group IV showed moderate immunoreactivity for TRX in 
the sarcoplasm of cardiomyocytes, with few positively 
immunostained nuclei of cardiomyocytes (Fig. 2D). The 
mean area per cent of strong positivity in this group was 
significantly decreased to 12.678 ± 3.828% compared 
to Group III. There were no significant differences in the 
mean area per cent of strong positivity between this 
group and both untreated control and curcumin-exposed 
groups (Table 2).
Biochemical study
Serum cardiac injury markers, namely troponin-T 
and CPK-MB, were significantly increased in Group III 
as compared to Group I and Group II. The intake 
of curcumin in autoimmune myocarditis group sig-
Figure 2. Heart sections immunostained with anti-thioredoxin antibody; A. Heart of rat from untreated control group; B. Heart of rat from 
curcumin-exposed group, all showing moderate immunoreactivity; C. Heart of rat from myocarditis group, showing intense immunoreactivity 
in sarcoplasm and nuclei (arrow); D. Heart of rat from myocarditis-curcumin group, showing moderate immunoreactivity of the sarcoplasm 
and few nuclei (arrow). Scale bars = 50 µm.
Table 2. Thioredoxin expression by immunohistochemistry (area percent of strong positivity) in cardiomyocytes
Group I: 
Control
Group II: 
Control-curcumin
Group III: 
Myocarditis
Group IV: 
Myocarditis-curcumin
Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI Mean ± SD 95% CI
Mean  
± SD
16.003  
± 4.139
12.543– 
–19.463
14.660  
± 9.977
7.523– 
–21.797
39.777  
± 7.297
32.119– 
–47.435
12.678  
± 3.808
9.954– 
–15.402
P1 0.976 0.0002* 0.738
P2 0.976 0.0002* 0.916
P3 0.0002* 0.0002* 0.0002*
*Significant difference (p ≤ 0.05); CI — confidence interval; SD — standard deviation; P1 vs. Group I; P2 vs. Group II; P3 vs. Group III 
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nificantly down-modulated the deviation in these 
markers compared to myocarditis group (Table 3). 
However, the values were still significantly higher than 
those of control and control-curcumin groups. No 
significant differences were observed between Group I 
and Group II. Serum pro-inflammatory biomarkers 
(TNF-a and IL-6) were elevated significantly in sera of 
Group III as compared to Group I and Group II. The 
administration of curcumin to rats with myocarditis 
significantly reduced the inflammatory cytokines levels 
compared to myocarditis group. However, their levels 
were still significantly higher than those of Group I 
and Group II. No significant differences were observed 
between the Group I and Group II (Table 3). 
DISCUSSION
Experimental autoimmune myocarditis in rat mo-
dels is characterised by severe myocardial changes 
with inflammatory cell infiltration [12]. Excessive 
oxidative stress, caused by either increased ROS 
production or inadequate antioxidant defences, 
can lead to cardiovascular diseases [9]. Excessive 
oxidant stress leads to the release of inflammatory 
cytokines and chemokines that regulate leucocyte 
trafficking into the heart. Finally, ROS can destroy 
cells by necrosis or apoptosis, leading to further 
myocardial injury [15].
Curcumin is the active ingredient in the traditio-
nal herbal remedy and dietary spice turmeric (Curcu-
ma longa). Curcumin has a wide range of beneficial 
properties, including inflammatory, antioxidant, che-
mopreventive and chemotherapeutic activity [4]. The 
pleiotropic activities of curcumin are derived from its 
complex chemistry, as well as, its ability to influence 
multiple signalling pathways. Curcumin is a free radi-
cal scavenger and hydrogen donor that exhibits both 
pro- and antioxidant activities. Furthermore, curcumin 
is remarkably non-toxic and exhibits limited bioavaila- 
bility [6]. Studies performed on rats have confirmed 
a lack of significant toxicity of curcumin when admini-
stered orally with doses up to 5 g/kg/day [17]. To the 
best of the authors’ knowledge, the dose selected in 
the present study is the lowest dose of curcumin used.
In the present study, immunohistochemistry for TRX 
was performed to examine the possible involvement of 
a redox regulating mechanism in the pathogenesis of 
immune-mediated myocarditis. Sections of the heart 
from myocarditis group showed a significant increase in 
the mean area per cent of strong positivity for TRX com-
pared to control and control-curcumin groups. Shioji et 
al. [14] suggested that enhanced TRX expression may be 
induced by ROS produced by infiltrating inflammatory 
cells in acute immune-mediated myocarditis which, in 
turn, induce translocation of TRX from the cytoplasm 
into the nucleus. The authors reported that TRX might 
have a protective role against the progressive myocardial 
damage in acute immune-mediated myocarditis. Such 
protective role could be explained by the ability of TRX 
to decrease protein oxidation, chemokine signalling, 
and leucocyte trafficking [16]. One simple explanation 
for the beneficial effect of TRX is that it scavenges ROS 
that would oxidise proteins, lipids and DNA [1]. Sections 
of the heart from myocarditis-curcumin group showed 
that the mean area of TRX expression in this group was 
significantly decreased compared to myocarditis group, 
while no significant difference was shown between 
myocarditis-curcumin and both untreated control and 
curcumin-exposed groups. The results of the present 
study suggested that administration of curcumin ame-
liorates cardiac myosin-induced autoimmune myocardi-
tis in rats, as evidenced by the decrease in TRX expression 
in that case. The present suggestion was also supported 
by the significant decrease in the serum levels of both 
cardiac injury markers (troponin-T and CPK-MB) and 
pro-inflammatory biomarkers (TNF-a and IL-6) shown in 
curcumin-myocarditis group compared with myocarditis 
group. The effect of curcumin could be attributed to its 
antioxidant and anti-inflammatory properties. However, 
the precise mechanism of the protective effect of cur-
cumin in the acute phase of autoimmune myocarditis 
Table 3. Biochemical parameters in the studied groups
Groups CPK-MB [U/L] Troponin-T [pg/mL] TNF-a [pg/mL] Interleukin-6 [pg/mL]
Group I (untreated control) 33.71 ± 3.89a 7.35 ± 1.53a 6.69 ± 1.13a 9.32 ± 0.44a
Group II (curcumin-exposed) 37.79 ± 5.28a 6.95 ± 0.87a 6.34 ± 0.59a 8.27 ± 1.25a
Group III (myocarditis) 174.58 ± 5.57b 40.82 ± 4.36b 26.75 ± 4.14b 29.81 ± 4.86b
Group IV (myocarditis-curcumin) 131.13 ± 2.37c 30.87 ± 1.94c 16.69 ± 1.57c 18.21 ± 1.57c 
Each value represents the mean ± standard deviation. The mean values not sharing a superscript alphabet in a column indicate significant difference at p < 0.05; CPK-MB — creatine 
phosphokinase MB isoenzyme; TNF-a — tumour necrosis factor alpha
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needs further investigation. It has been shown that 
curcumin significantly decreased plasma levels of IL-8, 
IL-10, TNF-a and cardiac troponin I in cases of rabbits 
underwent cardiopulmonary bypass (CPB). Further-
more, the appearance of apoptotic cardiomyocytes 
significantly decreased in the curcumin-CPB group. It 
was concluded that curcumin ameliorated the surge 
of pro-inflammatory cytokines during CPB and decre-
ased the occurrence of cardiomyocytic apoptosis after 
cardiac injury [19]. Regarding the limitations of the 
present study, the authors studied only the effect of 
curcumin on acute myocarditis. Therefore, a future 
study on chronic phase of autoimmune myocarditis 
would be essential. Also, measurement of the serum 
levels of TRX would be more accurate than TRX im-
munoreactivity in the wall of the heart performed in 
the present study. Due to the low number of evalua-
ted animals in each experimental group, the obtained 
data will be selected only as supporting data in the 
human risk evaluation.
CONCLUSIONS
In conclusion, the present study demonstrated that 
oral administration of curcumin ameliorates cardiac 
myosin-induced autoimmune myocarditis in rats, as 
evidenced by a significant reduction of TRX immuno-
reactivity, as well as, of the serum levels of both cardiac 
injury markers (troponin-T and CPK-MB) and pro-inflam-
matory biomarkers (TNF-a and IL-6). The authors would 
recommend the use of curcumin as a prophylactic and 
therapeutic agent for acute autoimmune myocarditis 
in human and encourage the estimation of serum level 
of TRX as a relevant indicator for the evaluation of the 
progress of acute myocarditis cases.
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